

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/786,016	02/26/2004	Tomoaki Hoshino	021310A	3540	
38834 7	590 12/15/2006		EXAM	EXAMINER	
	N, HATTORI, DANI	JIANG, DONG			
SUITE 700	CTICUT AVENUE, NW		ART UNIT	PAPER NUMBER	
WASHINGTO	N, DC 20036		1646		

DATE MAILED: 12/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)	
		10/786,016	HOSHINO, TOMOAKI	
	Office Action Summary	Examiner	Art Unit	
		Dong Jiang	1646	
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the	correspondence address	
WHIC - Externafter - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be to the state of the state	N. mely filed n the mailing date of this communication ED (35 U.S.C. § 133).	
Status				
	Responsive to communication(s) filed on 25 Second This action is FINAL . 2b) This Since this application is in condition for allower closed in accordance with the practice under Exercise 1.	action is non-final. nce except for formal matters, p		İs
Dispositi	on of Claims			
5)□ 6)□ 7)□ 8)⊠	Claim(s) <u>24 and 32-50</u> is/are pending in the ap 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) is/are rejected. Claim(s) is/are objected to. Claim(s) <u>24 and 32-50</u> are subject to restriction on Papers	vn from consideration.		
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction to the output of the correction of the oath or declaration is objected to by the Examination is objected to be a considered to b	epted or b) objected to by the drawing(s) be held in abeyance. So ion is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121((d).
Priority u	ınder 35 U.S.C. § 119			
a)[Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau See the attached detailed Office action for a list of	s have been received. s have been received in Applica ity documents have been receiv ı (PCT Rule 17.2(a)).	tion No red in this National Stage	
2) 🔲 Notic 3) 🔲 Inforn	t(s) e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	4) Interview Summar Paper No(s)/Mail D 5) Notice of Informal 6) Other:	oate	

Art Unit: 1646

DETAILED ACTION

Applicant's amendment filed on 25 October 2006 is acknowledged and entered.

Following the amendment, claim 24 is amended, and the new claims 32-50 are added.

Currently, claims 24 and 32-50 are pending.

Upon reviewing the new claims, second restriction requirement is warranted.

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 24, 32-39 and 40 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is a monoclonal antibody for IL-18, classified in class 424, subclass 141.1.
- II. Claims 24, 32-39 and 40 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is a monoclonal antibody for IL-18 receptor, classified in class 424, subclass 141.1.
- III. Claims 24, 32-39, 41, and 49 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is a substance inhibiting conversion of a precursor of IL-18 into an activated one, classified in classification depending upon the chemical entity of the substance.
- IV. Claims 24, 32-39, 42, and 49 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is an inhibitor of cysteine protease, classified in class 424, subclass 94.1.
- V. Claims 24, 32-39, 43, and 49 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is an IL-1β converting enzyme inhibitor, classification depending upon the chemical entity of the inhibitor.
- VI. Claims 24, 32-39, 44, and 49 in part, drawn to a composition comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-18 inhibitor is an IL-18BP, classified in class 514, subclass 2.

Application/Control Number: 10/786,016

Art Unit: 1646

VII. Claims 24, 32-39, 45 in part, 46, and 50 in part, drawn to a composition

comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the

IL-2 inhibitor is a monoclonal antibody for IL-2, classified in class 424, subclass

Page 3

141.1.

VIII. Claims 24, 32-39, 45 in part, 48, and 50 in part, drawn to a composition

comprising at least one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the

IL-2 inhibitor is a monoclonal antibody for IL-2 receptor, classified in class 424,

subclass 141.1.

IX. Claims 24, 32-39, 47, and 50 in part, drawn to a composition comprising at least

one of an IL-18 inhibitor and/or an IL-2 inhibitor, wherein the IL-2 inhibitor is an

IL-2-diphtheria toxin conjugate, classified in class 424, subclass 183.1.

The inventions are distinct, each from the other because:

Inventions I-IX are drawn to independent and unrelated products, which are physically

and functionally distinct chemical entities, and share neither structure nor function. Also, each is

not required for the manufacture of another. Thus, non-coextensive searches are required.

Because these inventions are distinct for the reasons given above and have acquired a

separate status in the art as shown by their different classification and/or recognized divergent

subject matters, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an

election of a species or invention to be examined even though the requirement be traversed (37)

CFR 1.143), and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve

a right to petition, the election must be made with traverse. If the reply does not distinctly and

specifically point out supposed errors in the restriction requirement, the election shall be treated

as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably

distinct, applicant should submit evidence or identify such evidence now of record showing the

inventions or species to be obvious variants or clearly admit on the record that this is the case. In

Application/Control Number: 10/786,016 Page 4

Art Unit: 1646

either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Application/Control Number: 10/786,016 Page 5

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication should be directed to Dong Jiang whose telephone number is 571-272-0872. The examiner can normally be reached on Monday - Friday

from 9:30 AM to 7:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Gary Nickol, can be reached on 571-272-0835. The fax phone number for the

organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Dong Jiang, Ph.D

Patent Examiner

AU1646 12/8/06